N

Neptune Medical

At-home fertility diagnostics and non-invasive device

Senior/Staff Linux Software Engineer - Robotics Platform

Full-Time
$185k - $225k/yr+ Equity + 401(k) match
Senior
Bachelor's, Master's
Burlingame, CA, USA
In Person
Software EngineeringEmbedded Engineering

About the job

Requirements
  • B.S. or M.S in Computer Science, Electrical Engineering, Electronics and Communication Engineering or related fields.
  • 5-7 years designing and developing software applications for embedded Linux systems.
  • Robust knowledge of C++ and Python.
  • Experience with Linux kernel development and/or NVIDIA’s embedded software stack desired.
  • Ability and flexibility to handle multiple responsibilities within the software team based on priorities.
  • Excellent communication and documentation skills.
Responsibilities
  • Design and implement the compute platform for the vision pipeline for the Triton robot.
  • Evaluate and prototype solutions for the control and vision subsystems using different computers and GPUs, optimizing for latency, efficiency and robustness.
  • Design, develop, document, verify, and continuously improve software for video pipelines using NVIDIA Jetson embedded systems: control cameras and display low-latency video, record video, composite video streams, and share video and camera metadata.
  • Work with deep-learning and computer-vision algorithms engineers to integrate new processing capabilities and AI applications into the product code.
  • Work with peer engineers on software design and code reviews.
  • Document software designs, reviews and processes.
Desired Qualifications
  • None

About the company

Neptune Medical develops devices and tests to address male infertility. Its two main products are Pro-Test, an at-home diagnostic kit that lets individuals test fertility parameters from home, and Neptune, a non-invasive device designed to improve sperm quality. Pro-Test provides a convenient way to assess fertility without clinic visits, while Neptune uses a proprietary, non-invasive method to enhance key sperm metrics and is intended for home use alongside clinical fertility treatment. The company serves both clinics (B2B) and individual consumers (B2C) and markets its products to help diagnose and treat male infertility, a factor in about half of all infertility cases. Neptune Medical differentiates itself by offering integrated, consumer-accessible diagnostics and treatment tools, backed by grant funding and participation in precision medicine programs, aiming to make diagnosis and treatment more private, accessible, and effective.

Company Size

1-10

Company Stage

Series D

Total Funding

$97M

Headquarters

Burlingame, California

Founded

2016

Get referred to Neptune Medical

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA clearance on September 16, 2026 unlocks U.S. hospital purchasing cycles.
  • Neptune expanded headcount to 155 employees by March 2026, supporting commercialization.
  • 2026 hiring and DDW study momentum signal active physician interest and pipeline execution.

What critics are saying

  • No public evidence shows meaningful revenue from Triton by October 5, 2026.
  • Pathfinder still is not available for sale outside the United States on October 3, 2026.
  • A missed commercial rollout for Triton would strand Neptune’s $97 million platform investment.

What makes Neptune Medical unique

  • Dynamic Rigidization makes Neptune’s scope control mechanically distinct from standard endoscopy.
  • Triton 1 won FDA clearance on September 16, 2026 for colon procedures.
  • Pathfinder reached 15,000 patients, proving clinical adoption before Triton’s launch.

Help us improve and share your feedback! Did you find this helpful?

Benefits

401(k) Company Match

Company Equity

Company News

The Robot Report
Oct 4th, 2024
Robotics Investments Near $1B In August

Listen to this articleSwiss-Mile raised $22M in August 2024 for its wheeled quadruped. Fifty producers of robots and robotics enabling technologies received funding in August 2024, pulling in a total of approximately $1 billion. This figure is on par with the $1.2 billion average The Robot Report has tracked each of the previous 12 months. Investment targeted to robotics companies for the first eight months of 2024 equals about $10.86 billion. You can follow The Robot Report‘s investment section here. The largest investments in August were secured by developers of autonomous driving technologies

Business Wire
Aug 17th, 2024
Neptune Medical Announces $97M Series D Financing and Spinout of Jupiter Endovascular

Neptune Medical announces $97 million in Series D financing, along with the spinout of its Jupiter Endovascular subsidiary.